HC Wainwright & Co. Maintains Neutral on IGM Biosciences, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a Neutral rating on IGM Biosciences and lowers the price target from $12 to $11.
September 05, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. has maintained a Neutral rating on IGM Biosciences and reduced the price target from $12 to $11, indicating a slightly bearish outlook.
The reduction in price target from $12 to $11 by HC Wainwright & Co. suggests a slightly bearish sentiment towards IGM Biosciences. Maintaining a Neutral rating indicates no strong buy or sell recommendation, but the lowered target may influence investor perception negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100